We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: HFpEF
MedXY News
EnglishTag

HFpEF

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Heart Failure in Portuguese Adults Aged 50 and Above: Insights from the PORTHOS Study on Prevalence and Predominant Phenotypes
CardiologyHFpEFepidemiology

Heart Failure in Portuguese Adults Aged 50 and Above: Insights from the PORTHOS Study on Prevalence and Predominant Phenotypes

By MedXY|Sep 15, 2026

The PORTHOS study reveals a 16.5% prevalence of heart failure among Portuguese adults aged 50+, with HFpEF constituting over 90% of cases, mostly undiagnosed, highlighting the need for enhanced screening strategies in aging populations.

Advancing Prognostic Precision in HFpEF: The LIFE-Preserved Risk Prediction Model
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
CardiologyHFpEFheart failure

Advancing Prognostic Precision in HFpEF: The LIFE-Preserved Risk Prediction Model

By MedXY|Sep 11, 2026

The LIFE-Preserved model accurately predicts short-term and lifetime risks of heart failure hospitalization or cardiovascular death in HFpEF patients, enabling tailored clinical risk stratification and improved management.

Unveiling the Role of Myeloid Cells in Right Ventricular Dysfunction in HFpEF via Sterile Inflammation
CardiologyHFpEFmyeloid cells

Unveiling the Role of Myeloid Cells in Right Ventricular Dysfunction in HFpEF via Sterile Inflammation

By MedXY|Aug 22, 2026

This article explores how myeloid cell expansion drives right ventricular dysfunction in HFpEF through sterile inflammation, highlighting translational insights from murine models and human studies.

Unmasking Silent Heart Failure in Diabetes: Insights from the TARTAN-HF Trial
CardiologydiabetesHFpEF

Unmasking Silent Heart Failure in Diabetes: Insights from the TARTAN-HF Trial

By MedXY|Aug 21, 2026

The TARTAN-HF trial demonstrated that targeted natriuretic peptide screening in high-risk diabetic patients uncovers a high prevalence of undiagnosed heart failure, mainly HFpEF, enabling earlier treatment initiation and improved clinical c

Personalized Risk Modeling of Interatrial Shunt Therapy in Heart Failure: Insights from the RELIEVE-HF Trial
CardiologyHFpEFinteratrial shunt

Personalized Risk Modeling of Interatrial Shunt Therapy in Heart Failure: Insights from the RELIEVE-HF Trial

By MedXY|Aug 15, 2026

The RELIEVE-HF trial reveals distinct predictors of outcomes after interatrial shunt implantation in HFrEF and HFpEF, enabling personalized risk modeling to identify patients likely to benefit from this therapy.

Unveiling Heart Failure with Preserved Ejection Fraction in Adults with Congenital Heart Disease: Prevalence, Characteristics, and Clinical Challenges
Cardiologycongenital heart diseaseHFpEF

Unveiling Heart Failure with Preserved Ejection Fraction in Adults with Congenital Heart Disease: Prevalence, Characteristics, and Clinical Challenges

By MedXY|Aug 12, 2026

This article explores the high prevalence of heart failure with preserved ejection fraction (HFpEF) in adults with congenital heart disease (ACHD), highlighting its clinical features, hospitalization burden, and under-treatment issues.

Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction
CardiologyHFpEFHuyết Áp Phổi

Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction

By MedXY|Jun 20, 2026

Unclassified pulmonary hypertension often reflects early-stage HFpEF linked to left heart and metabolic dysfunction, identifiable via dynamic right heart catheterization and metabolomics.

Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model
CardiologyelamipretideHFpEF

Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model

By MedXY|Jun 15, 2026

Elamipretide improved skeletal muscle force, titin phosphorylation, and atrophy in a HFpEF rat model, supporting cardiolipin stabilization as a promising mitochondrial-targeted strategy.

Elamipretide Restores Skeletal Muscle Performance in a HFpEF Rat Model by Stabilizing Mitochondria
CardiologyelamipretideHFpEF

Elamipretide Restores Skeletal Muscle Performance in a HFpEF Rat Model by Stabilizing Mitochondria

By MedXY|Jun 19, 2026

In a HFpEF rat model, Elamipretide improved muscle force, reduced titin abnormalities, and prevented atrophy, supporting cardiolipin stabilization as a potential strategy for exercise intolerance.

Can a Mitochondrial “Membrane Stabilizer” Restore Muscle Function in HFpEF? New Rat Data on Elamipretide
CardiologyelamipretideHFpEF

Can a Mitochondrial “Membrane Stabilizer” Restore Muscle Function in HFpEF? New Rat Data on Elamipretide

By MedXY|Jun 19, 2026

In a HFpEF rat model, elamipretide improved skeletal muscle force, reduced titin hyperphosphorylation, and prevented atrophy, supporting cardiolipin stabilization as a promising metabolic strategy.

Cardiolipin Stabilization Revives Skeletal Muscle Performance in a Preclinical HFpEF Model
CardiologyelamipretideHFpEF

Cardiolipin Stabilization Revives Skeletal Muscle Performance in a Preclinical HFpEF Model

By MedXY|Jun 19, 2026

In a rat model of HFpEF, the mitochondrial-targeted peptide elamipretide improved skeletal muscle force, reduced atrophy, and normalized titin phosphorylation, supporting cardiolipin stabilization as a promising mechanism.

SRPK3-Driven TPM1 Splicing Emerges as a Myofilament Mechanism of Diastolic Dysfunction in HFpEF
Cardiologyalternative splicingHFpEF

SRPK3-Driven TPM1 Splicing Emerges as a Myofilament Mechanism of Diastolic Dysfunction in HFpEF

By MedXY|Jun 9, 2026

A Circulation study identifies SRPK3-mediated alternative splicing of TPM1 exon 9a as a driver of myofibrillar disarray, reduced myocardial compliance, and diastolic dysfunction in HFpEF, highlighting a potential disease-modifying therapeut

Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk
CardiologyfinerenoneHFmrEF

Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk

By MedXY|May 19, 2026

In FINEARTS-HF, EMPEROR-Preserved biomarker-based risk models showed good prognostic discrimination in HFmrEF/HFpEF, and finerenone’s relative treatment effect was consistent across the full baseline risk spectrum.

Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial
Cardiologyatrial functional mitral regurgitationHFpEF

Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial

By MedXY|May 12, 2026

In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities
Cardiologycardiopulmonary exercise testingheart failure

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities

By MedXY|Apr 15, 2026

A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over

Ketone Esters in HFpEF: Metabolic Reprogramming and Hemodynamic Gains Fail to Translate into Improved Exercise Capacity
CardiologyCardiometabolicHFpEF

Ketone Esters in HFpEF: Metabolic Reprogramming and Hemodynamic Gains Fail to Translate into Improved Exercise Capacity

By MedXY|Jan 17, 2026

The KETO-HFpEF trial demonstrates that while acute ketone ester supplementation effectively induces ketosis and improves resting hemodynamics, it fails to improve peak oxygen consumption or exercise endurance in patients with heart failure

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF
Cardiologycardiac indexhemodynamics

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

By MedXY|Dec 29, 2025

A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF
CardiologyCardiologyHFpEF

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF

By MedXY|Dec 26, 2025

A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit exc

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF
CardiologyHFpEFNT-proBNP

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY|Dec 26, 2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial
Cardiologyclinical trialfinerenone

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY|Dec 26, 2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity,

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities